PMID | Jotup

EQS-News: Boditech Med and SphingoTec close Market Development Agreement to Boost Commercialization of Kidney Function Biomarker PenKid

Retrieved on:

목요일, 8월 31, 2023

Partnership, PMID, Acute kidney injury, Critical Care (journal), Hollinger, Septic shock, Risk, AKI, Kidney, Korea, Patient, Developed country, Renal replacement therapy, INT, Diagnosis, MDA, Medical device, Dietary supplement, Sepsis

In 2022, Boditech Med and SphingoTec closed a global licensing agreement to develop and offer the Proenkephalin A 119-159 (penKid) test on Boditech's automated immunoassay systems.

Key Points:

In 2022, Boditech Med and SphingoTec closed a global licensing agreement to develop and offer the Proenkephalin A 119-159 (penKid) test on Boditech's automated immunoassay systems.
The current market development agreement aims at enhancing the commercialization of the upcoming assay for penKid and ultimately advancing AKI diagnostics.
Gangwon-do, Republic of Korea and Hennigsdorf/Berlin, Germany, August 31, 2023 - Boditech Med Inc. (“Boditech”) and SphingoTec GmbH (“SphingoTec”) today announced they have entered into a market development agreement (MDA), building on their previous licensing collaboration for the kidney function biomarker penKid.
The MDA solidifies the partnership between Boditech and SphingoTec, aiming to support the successful commercialization of the assay for the biomarker penKid on the AFIAS platforms.

New Research Shows Potential Role for Mangos in Supporting Vascular Health and Antioxidant Activities

Retrieved on:

화요일, 8월 1, 2023

BOSTON, Aug. 1, 2023 /PRNewswire/ -- Mangos are one of the most popular fruits1 in the world, grown in more than 100 countries2 globally and consumed by an extremely diverse population. Now, two new studies funded by the National Mango Board and presented as posters during the American Society for Nutrition's Annual Conference (Nutrition 2023) show mangos may play a role in risk reductions for vascular issues while helping to improve antioxidant levels among relatively healthy adult men and women who are overweight or obese.

Key Points:

Mangos are one of the most popular fruits in the world, grown in 100+ countries and consumed by a diverse population.
"It's likely the unique matrix of vitamins and bioactive compounds synergistically working together that resulted in our findings," says Young Hong.
Following the first 12 weeks, participants took a 4-week washout break then switched groups and consumed the alternate snack for another 12 weeks.
Findings from the second study show a significant increase of glutathione peroxidase (GPX), a powerful antioxidant enzyme.

MRES: M2Bio Sciences Unveils an Exciting Line of Purple, White, and Green Teas from Kenya, Exhibiting Numerous Medicinal Health Benefits

Retrieved on:

월요일, 7월 17, 2023

This meticulously crafted collection of teas not only provides an exquisite sensory experience but also delivers exceptional medicinal health benefits.

Key Points:

This meticulously crafted collection of teas not only provides an exquisite sensory experience but also delivers exceptional medicinal health benefits.
Purple Tea offers remarkable health benefits, such as supporting cardiovascular health, boosting the immune system, and promoting healthy aging.
[2-3-4-6-7-8]
"We are delighted to introduce our exceptional line of Purple, White, and Green teas from Kenya," stated Jeff Robinson, CEO of M2Bio Sciences.
M2Bio Sciences invites tea enthusiasts and health-conscious individuals to embark on a transformative tea-drinking experience, harnessing the exceptional flavors and medicinal benefits of these extraordinary teas.

EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023

Retrieved on:

수요일, 7월 12, 2023

PMID, Huber loss, Onset, Brain, Comorbidity, The Different Forms of Flowers on Plants of the Same Species, Eisai, MRI, Pharmacokinetics, PLOS One, Co-promotion, Immunogenicity, Medical imaging, Pharmaceutical industry, Alzheimer's disease, Safety

This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety.

Key Points:

This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety.
There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.
Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, Lannfelt L, Pettersson FE.
Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.

New Preliminary Findings on Potential Response Indicator of Rakuten Medical's Alluminox Treatment from Phase 2 Window of Opportunity Study at SNMMI 2023

Retrieved on:

금요일, 6월 30, 2023

SAN DIEGO, June 30, 2023 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform, today announced that new interim evaluation data from the ASP-1929-103 study has been presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 Annual Meeting held from June 24 to 27. ASP-1929-103 is a Phase 2, open-label, single-arm, window of opportunity study* of Alluminox treatment (photoimmunotherapy: PIT) using an antibody-dye conjugate ASP-1929 with fluorescence imaging (ClinicalTrials.gov Identifier: NCT05182866) in patients with operable primary or recurrent head and neck squamous cell carcinoma (HNSCC) or cutaneous squamous cell carcinoma (cuSCC).

Key Points:

ASP-1929-103 is the very first clinical trial of Alluminox treatment in operable cancer.
As part of this trial, early time point (1 day) 18F-FDG PET/CT imaging was investigated as a potential response indicator of Alluminox treatment.
The preliminary, descriptive imaging analysis based on interim evaluation of 6 patients in ASP-1929-103 study presented during the meeting showed that 18F-FDG PET/CT imaging demonstrates a therapeutic response 1 day after Alluminox treatment using ASP-1929.
ASP-1929-103 is a Phase 2, open-label, single-arm, window of opportunity study* of Alluminox treatment (PIT) using an anti-EGFR antibody-dye conjugate, ASP-1929 with fluorescence imaging in patients with operable primary or recurrent HNSCC or cuSCC.

Guilt-Free Peanut Pleasures

Retrieved on:

화요일, 6월 27, 2023

ALBANY, Ga. , June 27, 2023 /PRNewswire/ -- A summer indulgence that's guilt-free and packed with nutrition is possible. It all starts with a base of peanut butter or peanuts since just one serving of this mighty superfood delivers protein, fiber, healthy fats and 19 vitamins and minerals.

Key Points:

In a food processor, blend together a 24-ounce container of full-fat cottage cheese, ½ cup peanut butter and ¼ cup plus two tablespoons maple syrup until smooth.
Stir in four chopped peanut butter cups and three tablespoons chopped peanuts.
Based in Albany, Ga., The Peanut Institute is a non-profit organization supporting nutrition research and developing educational programs to encourage healthful lifestyles that include peanuts and peanut products.
Consumption of peanut products improves memory and stress response in healthy adults from the ARISTOTLE study: A 6-month randomized controlled trial.

Philips' direct-to-angio stroke pathway: new analysis demonstrates substantial cost savings in addition to improved patient outcomes

Retrieved on:

수요일, 6월 14, 2023

Earlier results from this study demonstrated that a ‘Direct-to-Angio Suite’ (DTAS) pathway improves clinical outcomes for patients who have suffered a stroke.

Key Points:

Earlier results from this study demonstrated that a ‘Direct-to-Angio Suite’ (DTAS) pathway improves clinical outcomes for patients who have suffered a stroke.
“The ANGIOCAT clinical study has already shown that bringing stroke patients directly to the angio suite improves patient outcomes.
For stroke centers, a time-saving alternative is to have a dedicated angio-suite permanently on standby, to which stroke patients can be transferred immediately after admission.
Philips’ stroke portfolio includes solutions for stroke monitoring and communication in ambulances, tele-stroke patient assessment, diagnostic imaging and analysis, image-guided therapy, neurological monitoring and assessment, and more.

New Publication Highlights Basic Science Supporting Simufilam

Retrieved on:

월요일, 6월 12, 2023

PMID, Drug development, Cassava, Cassava Sciences, Doctor of Philosophy, Science, Alzheimer's disease, Patient, Research, Pharmaceutical industry, Neuroscience

Provides Overview of Basic Science Supporting Simufilam.

Key Points:

Provides Overview of Basic Science Supporting Simufilam.
AUSTIN, Texas, June 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced a new science publication in Drug Development Research, a peer-reviewed journal.
This article reviews certain receptor-protein interactions, including an overview of basic science supporting simufilam.
Simufilam is Cassava Sciences’ oral investigational drug candidate that is currently in Phase 3 clinical trials in patients with mild-to-moderate Alzheimer's disease dementia.

EQS-News: Eckert & Ziegler: PentixaPharm Receives BfArM-Clearance for its Therapeutic to conduct a Clinical Trial in Lymphoma

Retrieved on:

토요일, 6월 10, 2023

Lymphoma, PMID, Medical device, CXCR4, BFS, TecDAX, CNS, Teaching hospital, Radioligand, University Hospital (Newark, New Jersey), DOI, ISIN, Yttrium, T-cell lymphoma, Eckert, Safety, Pharmaceutical industry, Patient

The Yttrium-90 labelled CXCR4-compound PentixaTher will be tested as a radiotherapeutic against recurrent or refractory primary or isolated secondary central nervous system lymphoma.

Key Points:

The Yttrium-90 labelled CXCR4-compound PentixaTher will be tested as a radiotherapeutic against recurrent or refractory primary or isolated secondary central nervous system lymphoma.
The phase I/II, dose-finding study will be conducted at the University Hospital in Essen, North Rhine Westphalia, Germany.
The study will start after getting final endorsement from the German Radiation Safety Department (BfS),“ commented Dr. Hakim Bouterfa, Chief Medical Officer at Eckert & Ziegler.
C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma.

Independent clinical study shows Curonix’s Freedom® PNS System significantly reduces pain scores and medication usage

Retrieved on:

수요일, 6월 7, 2023

The results showed that patients significantly reduced both pain scores and medication usage, highlighting the Freedom PNS System as a successful, long-term, and less invasive treatment option for patients suffering from chronic pain.

Key Points:

The results showed that patients significantly reduced both pain scores and medication usage, highlighting the Freedom PNS System as a successful, long-term, and less invasive treatment option for patients suffering from chronic pain.
This independent retrospective study reviewed the electronic medical records of 57 patients over 24 months who were treated for different pain neuralgias with the Freedom PNS technology.
This further supports that the Freedom PNS System is an efficient and powerful treatment option for patients seeking long-term relief from their chronic pain.
Long-term consequences of chronic pain: mounting evidence for pain as a neurological disease and parallels with other chronic disease states.